To provide a novel microvesicle membrane protein and application thereof, and a method including a phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binding agent for microvesicle isolation, analysis, or binding for disease diagnosis or treatment.
There is provided an antibody against the cellular apoptosis susceptibility protein (CSE1L) or an antibody against the phosphorylated CSE1L, wherein the antibody is against the phosphorylated CSE1L. There is also provided an in vitro method of diagnosing cancer in a test subject comprising the steps of: (a) obtaining the test biological fluid sample from the test subject; (b) obtaining control samples from one or more normal subjects; (c) contacting the test biological fluid sample and the control samples in vitro with the antibody; (d) determining the amount of the CSE1L or the phosphorylated CSE1L in microvesicles in the test biological fluid sample; and (e) determining the amount of the CSE1L or the phosphorylated CSE1L in microvesicles in the control samples.
| JP2007282513A | 2007-11-01 |
| US20100120074A1 | 2010-05-13 |
JPN6014003414; Ｔａｉ ｅｔ ａｌ: Ｅｘｐｅｒｉｍｅｎｔａｌ Ｃｅｌｌ Ｒｅｓｅａｒｃｈ Ｖｏｌ． ３１６, 2010, ｐ． ２９６９-２９８１
JPN6014003406; Ｔｓａｉ ｅｔ ａｌ: Ｔｈｅ Ａｍｅｒｉｃａｎ Ｊｏｕｒｎａｌ ｏｆ Ｐａｔｂｏｌｏｇｙ Ｖｏｌ． １７６， Ｎｏ． ４, 201004, ｐ． １６１９-１６２８
JPN6014003408; Ｔｕｎｇ ｅｔ ａｌ: Ｃａｎｃｅｒ Ｅｐｉｄｅｍｉｏｌｏｇｙ， Ｂｉｏｍａｒｋｅｒｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｖｏｌ． １８， Ｎｏ． ５, 200905, ｐ． １５７０-１５７７
JPN6014003410; Ｓｃｈｅｒｆ ｅｔ ａｌ: Ｂｉｏｃｈｅｍｉｃａｌ ａｎｄ Ｂｉｏｐｈｙｓｉｃａｌ Ｒｅｓｅａｒｃｈ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ． ２５０, 1998, ｐ． ６２３-６２８
Hiroki Kaneo
Next Patent: ORGANIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE SAME